Pfizer and BioNTech have begun a clinical trial for their Omicron-specific Covid-19 vaccine candidate
The study will evaluate the vaccine for safety, tolerability and the level of immune response, as both a primary series and a booster dose, in up to 1,420 healthy adults ages 18 to 55.The study is broken up into three groups:Participants in the first cohort have received two doses of the current Pfizer Covid-19 vaccine at least 90 to 180 days before the study. They will receive one or two doses of the Omicron-specific vaccine.
"The companies have previously announced that they expect to produce four billion doses of the Pfizer-BioNTech COVID-19 Vaccine in 2022, and this capacity is not expected to change if an adapted vaccine is required."However, the companies also emphasized that people who have received booster doses of the current vaccine"maintain a high level of protection against Omicron, particularly against severe disease and hospitalizations.
Canada Latest News, Canada Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Pfizer starts clinical trial for omicron-specific Covid vaccineJUST IN: Pfizer and BioNTech announce that they have started a clinical trial testing a modified Covid-19 vaccine to protect against the omicron variant.
Read more »
Pfizer Begins Clinical Trial for Omicron-Specific COVID VaccinePfizer has begun a study comparing its original COVID-19 vaccine with doses specially tweaked to match the omicron variant
Read more »
Clinical Trials Begin For Pfizer And BioNTech’s Omicron-Specific Covid ShotI am a London-based reporter for Forbes covering breaking news. Previously, I have worked as a reporter for a specialist legal publication covering big data and as a freelance journalist and policy analyst covering science, tech and health. I have a master’s degree in Biological Natural Sciences and a master’s degree in the History and Philosophy of Science from the University of Cambridge. Follow me on Twitter theroberthart or email me at rhartforbes.com
Read more »
Pfizer says it's starting clinical studies of an omicron-based COVID-19 vaccinePfizer and BioNTech said Tuesday they've stated clinical trials for an omicron-based COVID-19 vaccine.
Read more »
Clinical Trials Begin For Pfizer And BioNTech’s Omicron-Specific Covid ShotI am a London-based reporter for Forbes covering breaking news. Previously, I have worked as a reporter for a specialist legal publication covering big data and as a freelance journalist and policy analyst covering science, tech and health. I have a master’s degree in Biological Natural Sciences and a master’s degree in the History and Philosophy of Science from the University of Cambridge. Follow me on Twitter theroberthart or email me at rhartforbes.com
Read more »
Pfizer Begins Clinical Trial For Omicron-Targeting VaccinePfizer has begun a study comparing its original COVID-19 vaccine with doses specially tweaked to match the omicron variant.
Read more »